US$83.82+1.0%11月13日 收盘
数据截至2026年9月30日，来自2026年11月5日提交的10-Q
公司指引：2026 财年营收 US$9.2B 至 US$9.3B — 同比下降 2.1%（上年同期 US$9.5B）
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$2.4B | US$2.4B | -1.28% |
| 利润 | US$591M | US$721M | -18.03% |
| 每股收益 | US$1.44 | US$1.63 | -11.66% |
| 自由现金流 | US$717M | US$798M | -10.15% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
“Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock 3 | producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com. 1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures. 2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. DISCLOSURE NOTICES
公司自己的描述，取自公告末尾。
引述和公司简介来自 Zoetis Inc. 于 2026年11月5日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Just reported
From Zoetis Inc.'s results release of 2026年11月5日; its quarterly report has since been filed.
Actual
US$2.39B
-1.3% y/y
-3.1% q/q
Guided
—
No guide given
Actual
US$1.44
-12% y/y
-13% q/q
Guided
—
No guide given
EPS, adjusted: US$1.75
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
每场电话会的简短摘要——本季度的表现、管理层的预期，以及他们是否兑现了上次所说的话——下方附完整文字记录。
Zoetis Inc. reported on 2026年11月5日. We are fetching the call transcript; its summary follows once the transcript is in.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
电话会摘要属于 Pro 内容
两分钟读完 Zoetis Inc. 的每场业绩电话会：关键数字、管理层的预期、是否兑现了上季度的展望，以及分析师提出但未获回答的问题。
先在 , , , 或 上看一份——向所有人开放。
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。